UBS Knock-Out ABT/ DE000UH4TNY1 /
2024-09-02 1:58:59 PM | Chg.-0.110 | Bid2:27:28 PM | Ask2:27:28 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.450EUR | -3.09% | 3.450 Bid Size: 5,000 |
3.500 Ask Size: 5,000 |
Abbott Laboratories | 150.8661 USD | 2078-12-31 | Put |
GlobeNewswire
08-06
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
GlobeNewswire
06-06
Circana’s 2023 New Product Pacesetters Report Reveals Innovation Is Meeting Consumers in New Moments
GlobeNewswire
05-09
R3 Vascular Announces $87 Million in Series B Financing and Appoints Christopher M. Owens as new Pre...
GlobeNewswire
03-25
Tricares Announces the Appointment of Ahmed Elmouelhi as President & Chief Executive Officer
GlobeNewswire
03-15
Attention Reckitt Benckiser Group investors: Portnoy Law Firm Announces Investigation into Reckitt B...
GlobeNewswire
2023-11-14
NeuroOne® Appoints Medtech Executive Christopher R. Volker as Chief Operating Officer and Reports In...
GlobeNewswire
2023-10-19
Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer
GlobeNewswire
2023-10-10
Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO
GlobeNewswire
2023-10-02
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors